ESMO 2022 Conference Coverage

 

Lung
09:38

ESMO 2022 Conference Coverage

Sotorasib vs. Docetaxel for Previously Treated NSCLC With KRAS G12C Mutation: CodeBreaK 200 Phase III Study

FEATURING Melissa Johnson
  • 737 views
  • December 30, 2022
  • 2
07:29

ESMO 2022 Conference Coverage

ESMO 2022 Updated Results From ADAURA: Osimertinib as Adjuvant Therapy in Patients With Resected EGFRm Stage IB–IIIA NSCLC

FEATURING Tom John
  • 652 views
  • November 8, 2022
  • 3
07:29

ESMO 2022 Conference Coverage

[private - new video will be uploaded] ESMO 2022 Updated Results From ADAURA: Osimertinib as Adjuvant Therapy in Patients With Resected EGFRm Stage IB–IIIA NSCLC

FEATURING Tom John
  • 80 views
  • October 18, 2022
  • 1
07:36

ESMO 2022 Conference Coverage

ESMO 2022 on the CheckMate 9LA Study Results: Clinical Outcomes in Patients With Tumor PD-L1<1% With 1L Nivo + Ipi + 2 Cycles of Chemo vs. Chemo Alone for mNSCLC

FEATURING Tom John
  • 260 views
  • October 18, 2022
  • 1
04:33

ESMO 2022 Conference Coverage

ESMO 2022 on the Phase III JIPANG Study: Final OS Analysis of Pemetrexed/Cisplatin vs. Vinorelbine/Cisplatin for Completely Resected Non-Squamous NSCLC

FEATURING Kiyotaka Yoh
  • 159 views
  • October 11, 2022
  • 2
20:57

Paul Hofman

Updates in Precision Approaches to the Molecular Diagnosis of NSCLC

  • 113 views
  • October 11, 2022
  • 1
07:24

ESMO 2022 Conference Coverage

ESMO 2022 on the Inflammatory Biomarkers as a Prognostic Scoring Model for Malignant Peritoneal Mesothelioma

FEATURING Keval Yerigeri
  • 17 views
  • October 10, 2022
08:38

ESMO 2022 Conference Coverage

ESMO 2022: Tissue and Liquid Biopsy Utilization in Advanced NSCLC in a Large Community US Practice

FEATURING Lucio Gordan
  • 295 views
  • October 10, 2022
  • 2
01:23

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the IPSOS Phase 3 Study: 1L Atezo vs. Single-Agent Chemo in Patients With NSCLC Not Eligible for a Platinum-Containing Regimen

FEATURING Siow Ming Lee
  • 15 views
  • September 30, 2022
16:05

ESMO 2022 Conference Coverage

ESMO 2022 on the IPSOS Phase 3 Study: 1L Atezo vs. Single-Agent Chemo in Patients With NSCLC Not Eligible for a Platinum-Containing Regimen

FEATURING Siow Ming Lee
  • 71 views
  • September 30, 2022
10:02

ESMO 2022 Conference Coverage

ESMO 2022 on the SYMPRO-Lung Trial: Patient-Reported Symptom Monitoring Improves Health-Related Quality of Life in Lung Cancer Patients

FEATURING Nicole Billingy
  • 33 views
  • September 27, 2022
36

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the INCREASE Trial: Ipi + Nivo & CRT Followed by Surgery in Resectable and Borderline-Resectable Lung Cancer

FEATURING Idris Bahce
  • 10 views
  • September 27, 2022
10:04

ESMO 2022 Conference Coverage

ESMO 2022 on the INCREASE Trial: Ipi + Nivo & CRT Followed by Surgery in Resectable and Borderline-Resectable Lung Cancer

FEATURING Idris Bahce
  • 41 views
  • September 27, 2022
02:57

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the Additional Practice-Informing Adverse Event Patterns and Management in the KRYSTAL-1 Phase 2 Study: Adagrasib in KRASG12Cm NSCLC

FEATURING Jun Zhang
  • 10 views
  • September 27, 2022
08:22

ESMO 2022 Conference Coverage

ESMO 2022 on the Additional Practice-Informing Adverse Event Patterns and Management in the KRYSTAL-1 Phase 2 Study: Adagrasib in KRASG12Cm NSCLC

FEATURING Jun Zhang
  • 272 views
  • September 27, 2022
  • 2
45

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on Outcomes of Real World Patients With Advanced NSCLC and High PD-L1 Expression Receiving 1L Immune Checkpoint Inhibitor Therapy

FEATURING Melinda Hsu
  • 10 views
  • September 27, 2022
06:07

ESMO 2022 Conference Coverage

ESMO 2022 on Outcomes of Real World Patients With Advanced NSCLC and High PD-L1 Expression Receiving 1L Immune Checkpoint Inhibitor Therapy

FEATURING Melinda Hsu
  • 96 views
  • September 27, 2022
  • 2
09:10

ESMO 2022 Conference Coverage

ESMO 2022 on Fine-Tuning Molecular Profiling in Advanced NSCLC

FEATURING Florian Länger
  • 92 views
  • September 27, 2022
  • 1
01:36

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the Controversies in Radiotherapy in SCLC Treatment

FEATURING Bjørn Henning Grønberg
  • 16 views
  • September 16, 2022
19:57

ESMO 2022 Conference Coverage

ESMO 2022 on the Controversies in Radiotherapy in SCLC Treatment

FEATURING Bjørn Henning Grønberg
  • 241 views
  • September 16, 2022
03:24

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the Results of the Randomized DICIPLE Phase 3 Trial: Nivo + Ipi 6-Month Treatment vs. Continuation in Advanced NSCLC

FEATURING Gerard Zalcman
  • 16 views
  • September 15, 2022
08:26

ESMO 2022 Conference Coverage

ESMO 2022 on the Results of the Randomized DICIPLE Phase 3 Trial: Nivo + Ipi 6-Month Treatment vs. Continuation in Advanced NSCLC

FEATURING Gerard Zalcman
  • 1,093 views
  • September 15, 2022
  • 2